A Phase 2 Study to Evaluate the Efficacy and Safety of Live SK08 Powder in Adult Patients with Active Mild to Moderate Ulcerative Colitis
Phase 2
Not yet recruiting
- Conditions
- Ulcerative Colitis (UC)
- Interventions
- Drug: Placebo
- First Posted Date
- 2024-12-09
- Last Posted Date
- 2024-12-16
- Lead Sponsor
- Guangzhou Zhiyi Biotechnology Co., Ltd.
- Target Recruit Count
- 60
- Registration Number
- NCT06725017
A Study to Evaluate the Efficacy and Safety of Live SK08 Powder in Patients With IBS-D
Phase 3
Recruiting
- Conditions
- Irritable Bowel Syndrome With Diarrhea
- Interventions
- Drug: Placebo
- First Posted Date
- 2024-02-07
- Last Posted Date
- 2025-04-03
- Lead Sponsor
- Guangzhou Zhiyi Biotechnology Co., Ltd.
- Target Recruit Count
- 1298
- Registration Number
- NCT06247046
- Locations
- 🇨🇳
Wuxi People's Hospital, Wuxi, Jiangsu, China
🇨🇳Binzhou Medical University Hospital, Binzhou, Shandong, China
A Sequential Single and Multiple Ascending Dose (SAD/MAD) Study of SK10 Powders in Healthy Adult Subjects
- First Posted Date
- 2023-09-07
- Last Posted Date
- 2024-02-20
- Lead Sponsor
- Guangzhou Zhiyi Biotechnology Co., Ltd.
- Target Recruit Count
- 24
- Registration Number
- NCT06026397
- Locations
- 🇺🇸
Early Phase Clinical Unit (EPCU) - PAREXEL, Glendale, California, United States
© Copyright 2025. All Rights Reserved by MedPath